drugset / Trial / NCT00123318
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
Phase 3
Completed
52 enrolled
Trans Tasman Radiation Oncology Group
The Royal Australian and New Zealand College of Radiologists · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with radiotherapy.
Timeline
- Start
- 2003-02
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Epirubicin | Small molecule | 50 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 225 mg/m2 | Intravenous |